Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL4668173 | 0.97 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6147449 | 0.89 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5885636 | 0.83 | LOXL2 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10821032 | 0.81 | CA1 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10287538 | 0.80 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14281812 | 0.80 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| Butane SCHEMBL10937269 | 0.79 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1 | |
| Butane SCHEMBL6056649 | 0.79 | KMT2A (0.48) | LMNAMAOASMN1; SMN2HTTKMT2A | |
| SCHEMBL6147369 | 0.79 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL128190 | 0.79 | CA1 (0.70) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101138559-A | Novel medicine preparations for curing psoriasis | SHANGHAI XINSHENGYUAN BIOLOG M (CN) | 2008-03-12 | — | — | CN | disclosed |
| CN-101134028-A | Artinoid ethyltester capsule | SHANGHAI NEW SHENGYUAN MEDICAL (CN) | 2008-03-05 | — | — | CN | disclosed |
| EP-1280757-B1 | NEW GAMMA SELECTIVE RETINOIDS | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-6603012-B2 | RAR selective retinoid agonists | HOFFMANN-LA ROCHE INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1280757-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20020026060-A1 | RAR selective retinoid agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | US | disclosed |
| WO-2001083438-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| CN-1049423-C | Aromatic carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-02-16 | — | — | CN | disclosed |
| CN-1105981-A | Aromatic carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
| EP-0626940-A1 | SUBSTITUTED PHENYLETHENYL COMPOUNDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5326898-A | Substituted phenylethenyl compounds having retinoid-like biological activity | ALLERGAN, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1993016029-A1 | SUBSTITUTED PHENYLETHENYL COMPOUNDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026060-A1 | RAR selective retinoid agonists | RARA, RARG, RARB | CA12 920/4885CA1 1097/4885CA2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.